Stock Ratings / Health Care / DRIO / options

BEAT (50) NEPH (73) CVRX (43) XTNT (69) ⌘ Pro Terminal →

DarioHealth Corp. (DRIO) Options Positioning, Max Pain & Unusual Sweeps

Q: Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DarioHealth Corp. (NASDAQ: DRIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.31 (-2.93% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRIO ranks #795 in composite RQD confidence.

Q: How does DRIO compare to BEAT and NEPH in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $30.4M) and NEPH (Nephros Inc.) posts a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for DRIO?

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is DRIO trading relative to its 50-day, 200-day, and 52-week technical levels?

DRIO last traded at $3.31 (-2.93% on volume of 59,443 shares), positioning the stock -44.65% below its 50-day simple moving average ($5.98) and -57.24% below its 200-day simple moving average ($7.74). Across its 52-week range of $3.00 to $14.77, DRIO sits at the 2.6% percentile with a 14-day RSI of 23.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

Q: What is DRIO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DRIO.

$3.31 -2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.29

DarioHealth Corp. (DRIO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $32.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.29 (-0.72%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY DRIO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.6% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (25% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 23.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.80-16.9% Next Q

Q2 (-2Q)

Grade D$4.82-21.8% Next Q

Q3 (-1Q)

Grade E$3.77-12.2% Next Q

Current

Grade D-$3.31-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRIO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.98) and Max Pain ($3.48) forces dealer call-delta covering toward $15.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DRIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (DRIO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for DRIO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRIO)

✓Walkthrough of DRIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.64%▼ SUPPORT BREAKDOWN

2026-10-30O $3.03H $3.32L $3.00C $3.31VOL 55.5K

RES: $7.54SUP: $3.88SMA50: $5.98SMA200: $7.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRIO Butterfly Map → + Track DRIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRIO)

Health Care Rank #795 of 1016 ⚔️ BEAT vs DRIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRIO vs. BEAT, NEPH, CVRX, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DarioHealth Corp. (DRIO) ranks #795 by composite RQD confidence (36/100, grade D-) and #794 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with DRIO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRIO ACTIVE DarioHealth Corp.	D-	36/100	—	56.6%	-35.0%	-2.93%	$32.4M	Benchmark Subject
BEAT Heartbeam Inc.	D	50/100	—	—	-35.0%	+1.34%	$30.4M	/beat-vs-drio →
NEPH Nephros Inc.	B	73/100	29.8x	61.9%	18.9%	+3.16%	$35.5M	/neph-vs-drio →
CVRX CVRx Inc.	D-	43/100	—	85.3%	-35.0%	+1.79%	$38.0M	/cvrx-vs-drio →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-drio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533998

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DarioHealth Corp. (DRIO) reported GAAP revenue of $22.4M (-17.3% vs. FY2024 revenue of $27.0M ) , GAAP net income of -$41.7M, operating cash flow of -$25.9M, and free cash flow of -$26.1M (+32.6% YoY). On the balance sheet, DRIO closed FY2025 with $110.1M in total assets against $30.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$22.4M	-$41.7M	-$25.9M	-$26.1M	$110.1M	$30.7M
FY2024 (FY)	2024-12-31	$27.0M	-$42.7M	-$38.6M	-$38.7M	$118.9M	$23.5M
FY2023 (FY)	2023-12-31	$0	-$59.4M	-$30.4M	-$30.4M	—	—

3. DRIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DarioHealth Corp. (NASDAQ: DRIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.31 (-2.93% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRIO ranks #795 in composite RQD confidence.

How does DRIO compare to BEAT and NEPH in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $30.4M) and NEPH (Nephros Inc.) posts a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRIO?

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRIO trading relative to its 50-day, 200-day, and 52-week technical levels?

DRIO last traded at $3.31 (-2.93% on volume of 59,443 shares), positioning the stock -44.65% below its 50-day simple moving average ($5.98) and -57.24% below its 200-day simple moving average ($7.74). Across its 52-week range of $3.00 to $14.77, DRIO sits at the 2.6% percentile with a 14-day RSI of 23.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

DRIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DRIO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for DRIO.

Direct Sub-Reports: DRIO RQD Cockpit DRIO 12M Forecast DRIO Earnings & Move DRIO Dividends & DRIP DRIO Insiders & 13F DRIO Whale Options DRIO Profit Sankey DRIO News & Why